Stay updated on M7824 with Gemcitabine in Advanced Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the M7824 with Gemcitabine in Advanced Pancreatic Cancer Clinical Trial page.

Latest updates to the M7824 with Gemcitabine in Advanced Pancreatic Cancer Clinical Trial page
- Check5 days agoChange DetectedMaryland has been added as a study location in the Locations section. The page revision has been updated from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2; no observable changes to study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check33 days agoChange DetectedVersion label updated from v3.2.0 to v3.3.1. No changes were made to the study details or content.SummaryDifference0.0%

- Check41 days agoChange DetectedRemoved the funding-related notice about potential data currency issues and operating status (including links to cc.nih.gov and opm.gov). This was an administrative notice and does not alter the trial details.SummaryDifference0.3%

- Check55 days agoChange DetectedNo significant additions or deletions of core study content were observed; the layout shows minor visual differences without altering the Study Overview, Eligibility Criteria, or other essential sections. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check84 days agoChange Detected- Added a government funding lapse notice and current operating status guidance for NIH Clinical Center, and a version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference2%

Stay in the know with updates to M7824 with Gemcitabine in Advanced Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the M7824 with Gemcitabine in Advanced Pancreatic Cancer Clinical Trial page.